CoLucid Pharmaceuticals, Inc.
902 North Capitol Avenue
Suite 302
Indianapolis
Indiana
46204
United States
Tel: 317-684-6703
44 articles about CoLucid Pharmaceuticals, Inc.
-
Eli Lilly Completes Acquisition Of CoLucid Pharma
3/1/2017
-
Massachusetts' CoLucid Pharma Surges on $960 Million Eli Lilly Buyout Deal
1/19/2017
-
CoLucid Pharma Provides SPARTAN Enrollment Update
11/14/2016
-
CoLucid Pharma Announces 2016 Third Quarter Results And Corporate Highlights
11/9/2016
-
CoLucid Pharma Announces Additional Analyses Of Lasmiditan’s Onset Of Action Data From SAMURAI And Supporting Non-Clinical Data
10/6/2016
-
CoLucid Pharma To Present At The Ladenburg Thalmann 2016 Healthcare Conference
9/26/2016
-
CoLucid Pharma Provides Interim Update On GLADIATOR
9/19/2016
-
CoLucid Pharma Announces Achievement Of Secondary Endpoints In SAMURAI
9/19/2016
-
CoLucid Pharma Announces Pricing Of Public Offering Of Common Stock
9/9/2016
-
Cambridge's CoLucid Pharma Rockets on Late-Stage Migraine Data
9/7/2016
-
CoLucid Pharma Announces 2016 Second Quarter Results and Corporate Highlights
8/10/2016
-
CoLucid Pharma Completes Enrollment for SAMURAI Phase III Study Evaluating Oral Lasmiditan
6/8/2016
-
CoLucid Pharma And IMS Health Publish White Paper To Address Migraine Market Misperceptions
1/5/2016
-
CoLucid Pharma Announces Appointment Of Dr. Raymond Skwierczynski As Head, Pharmaceutical Operations
12/8/2015
-
CoLucid Pharma Provides SAMURAI Enrollment Update
11/30/2015
-
CoLucid Pharma To Present Corporate Overview At The Stifel 2015 Healthcare Conference
11/12/2015
-
CoLucid Pharma Announces Third Quarter 2015 Results And Corporate Highlights
11/10/2015
-
CoLucid Pharma Announces Election Of Mark Corrigan, M.D., To Board Of Directors
10/27/2015
-
CoLucid Pharma Announces Initiation Of Phase III Long-Term, Open-Label Trial Of Lasmiditan In Migraine
10/8/2015
-
CoLucid Pharma To Present At Two Investor Conferences In September
9/3/2015